New combo therapy aims to personalize throat cancer treatment

NCT ID NCT07428148

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new approach for people with a certain type of throat cancer that is not low-risk. Participants first receive a combination of chemotherapy, immunotherapy, and a special type of radiation called lattice radiotherapy. Then, based on how much the tumor shrinks, they get either a shorter or longer course of standard chemoradiation. The goal is to see if this personalized plan is safe and effective. About 60 people will take part in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
carboplatin, paclitaxel, pembrolizumab, and lattice radiotherapy
What this could lead to
If successful, this could lead to a more personalized, effective treatment for throat cancer that reduces side effects by tailoring radiation dose to how well the tumor responds.
What could go wrong
This is an early-phase trial with only 60 participants, so results may not apply to everyone. The combination therapy may cause significant side effects, and the optimal dose is still being determined.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

oropharynx squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • NYU Langone Health

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.